Inhibition of Glucose Trimming with Castanospermine Reduces Calnexin Association and Promotes Proteasome Degradation of the α-Subunit of the Nicotinic Acetylcholine Receptor*

Abstract

To identify factors involved in the expression of ligand-gated ion channels, we expressed nicotinic acetylcholine receptors in HEK cells to characterize roles for oligosaccharide trimming, calnexin association, and targeting to the proteasome. The homologous subunits of the acetylcholine receptor traverse the membrane four times, contain at least one oligosaccharide, and are retained in the endoplasmic reticulum until completely assembled into the circular arrangement of subunits of δ-α-γ-α-β to enclose the ion channel. We previously demonstrated that calnexin is associated with unassembled subunits of the receptor, but appears to dissociate when subunits are assembled in various combinations. We used the glucosidase inhibitor castanospermine to block oligosaccharide processing, and thereby inhibit calnexin’s interaction with the oligosaccharides in the receptor subunits. Castanospermine treatment reduces the association of calnexin with the α-subunit of the receptor, and diminishes the intracellular accumulation of unassembled receptor subunit protein. However, treatment with castanospermine does not appear to alter subunit folding or assembly. In contrast, co-treatment with proteasome inhibitors and castanospermine enhances the accumulation of polyubiquitin-conjugated α-subunits, and generally reverses the castanospermine induced loss of α-subunit protein. Co-transfection of cDNAs encoding the α- and δ-subunits, which leads to the expression of assembled α- and δ- subunits, also inhibits the loss of α-subunits expressed in the presence of castanospermine. Taken together, these observations indicate that calnexin association reduces the degradation of unassembled receptor subunits in the ubiquitin-proteasome pathway.

Footnotes

  • * This work was supported by United States Public Health Service Fellowship NS09715 (to S. H. K.), National Institutes of Health Grant NS11323, MDA, and Smokeless Tobacco Research Council, Inc. grants (to J. L.), and United States Public Health Service Grant GM18360 (to P. T.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • 1 The abbreviations used are: CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate; Bgt, bungarotoxin; CST, castanospermine; ER, endoplasmic reticulum; HEK, human embryonic kidney; Me2SO, dimethyl sulfoxide; LAC, lactacystin; Z-LLF-CHO, benzyloxycarbonyl-Leu-Leu-phenylalaninal; mAb, monoclonal antibody.

  • 2 S. Keller, unpublished data.

    • Received September 15, 1997.
    • Revision received April 14, 1998.
« Previous | Next Article »Table of Contents
  • Advertisement
  • Advertisement
Advertisement